ArticleEuropean journal of epidemiology2026
Life expectancy of people with hemophilia in France in 2022.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The life expectancy of adult people with hemophilia has significantly increased thanks to therapeutic advancements, especially after the bloodborne infectious risks were controlled. However, no French data has yet documented this improvement. This study aims to compare the life expectancy of French people with hemophilia to that of the general population. A longitudinal study was conducted on 9,928 people with hemophilia included in the FranceCoag database between 1994 and 2022. Life expectancies were calculated using abridged life tables The life expectancies for people with hemophilia were 66.3 years at age 20 (mild hemophilia = 68.8, moderate = 64.8, severe = 60.4) and 47.5 years at age 40 (mild = 49.2, moderate = 45.9, severe = 42.7). Individuals with mild or moderate hemophilia had higher life expectancies compared to general population (59.8 years at age 20 and 40.7 years at age 40, p < 0.001). Those with severe hemophilia had a similar or slightly higher life expectancy at age 40. The mean differences in LE at ages 20 and 40, compared with the general population, varied markedly by severity, ranging from 0 to 10 years. Taken together, these findings suggest broadly comparable life expectancy in people with hemophilia, although differences remain according to disease severity. This improvement may be attributable both to recent therapeutic innovations and to more frequent and comprehensive medical follow-ups compared to the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.